115 related articles for article (PubMed ID: 29194690)
21. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
22. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
23. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.
Hoy JJ; Kallifatidis G; Smith DK; Lokeshwar BL
Sci Rep; 2017 Jun; 7(1):3058. PubMed ID: 28596572
[TBL] [Abstract][Full Text] [Related]
26. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
27. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells.
Sanderson JT; Clabault H; Patton C; Lassalle-Claux G; Jean-François J; Paré AF; Hébert MJ; Surette ME; Touaibia M
Bioorg Med Chem; 2013 Nov; 21(22):7182-93. PubMed ID: 24080105
[TBL] [Abstract][Full Text] [Related]
29. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
31. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
Kim W; Jones JO; Diamond M; Haqq C; Molina A; Small EJ; Ryan CJ
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):292-9. PubMed ID: 25047002
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
[TBL] [Abstract][Full Text] [Related]
35. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
37. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
38. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
Alimirah F; Chen J; Basrawala Z; Xin H; Choubey D
FEBS Lett; 2006 Apr; 580(9):2294-300. PubMed ID: 16580667
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
40. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]